PORTLAND, Ore.--(BUSINESS WIRE)--Bioject Medical Technologies Inc. (OTCBB:BJCT), a leading developer of needle-free injection therapy systems (NFITS), today announced that the Centers for Disease Control and Prevention (CDC) and its collaborating institutions presented the latest results of its clinical trial of the Biojector® 2000 at the 13th Annual Conference on Vaccine Research, sponsored by the National Foundation for Infectious Diseases and held in Bethesda, Maryland April 26 - 28, 2010. The study involved administering influenza vaccine intradermally in reduced “dose-sparing” amounts into the skin by jet injection, increasing the speed and avoiding the risks and discomfort of the traditional “Mantoux” needle method commonly used for tuberculosis skin testing.
